Table 1:
Baseline Patient Characteristics
| Characteristic | Total Cohort N = 6,754 |
|---|---|
| Age of cancer diagnosis (years) | |
| Median (IQR*) | 57 (47–65) |
| Female | 3,898 (58%) |
| Male | 2,856 (42%) |
| White | 5,762 (85%) |
| Black | 703 (10%) |
| Unknown | 109 (2%) |
| Multiracial/Multicultural | 93 (1%) |
| Asian | 75 (1%) |
| American Indian/Alaska Native | 8 (<1%) |
| Native Hawaiian/Pacific Islander | 4 (<1%) |
| Median body mass index (kg/m2) | 27 |
| ≥30 | 2,314 (34%) |
| 25–29.9 | 2,091 (31%) |
| <25 | 2,349 (35%) |
| Hypertension | 1,898 (28%) |
| Current/ previous smoker | 3,380 (50%) |
| Hyperlipidemia | 1,555 (23%) |
| Diabetes mellitus | 698 (10%) |
| Cancer type | |
| Breast | 1,999 (30%) |
| Lymphoma | 1,246 (18%) |
| Leukemia | 842 (12%) |
| Gastro-Intestinal | 614 (9%) |
| Multiple myeloma | 606 (9%) |
| Genito-Urinary | 541 (8%) |
| Lung | 280 (4%) |
| Myelodysplastic syndrome | 190 (3%) |
| Sarcoma | 168 (2%) |
| Other | 144 (2%) |
| Head and Neck | 124 (2%) |
| Chemotherapy type | |
| Anthracycline | 2,768 (41%) |
| HER2 Neu inhibitor | 914 (14%) |
| Kinase inhibitor | 794 (12%) |
| Other | 2,278 (34%) |
| Radiation | 2,908 (43%) |
| Medications | |
| Aspirin | 1,650 (24%) |
| †ACE inhibitor/ ‡ ARB | 1,729 (26%) |
| Beta blocker | 3,272 (48%) |
| Statin | 1,480 (22%) |
Abbreviations:
*
IQR, inter-quartile range
†
ACE, angiotensin converting enzyme
‡
ARB, angiotensin receptor blocker.